Mr Mrs Miss Ms Dr Other

Dr
Amy
Dawson

Patent Attorney

Glasgow Office

Life sciences

Telephone. +44(0) 141 229 5800
Email. adawson@hgf.com
Vcard
Linkedin

Experience

Amy joined HGF Glasgow in May 2020 as part of the Life Sciences group.

She graduated from the University of Glasgow with a first-class MSci in Immunology with Work Placement. This included a 12-month placement at GlaxoSmithKline R&D. Amy completed a PhD in Cancer Studies from the University of Glasgow. Her research involved using single cell RNA sequencing technology and proteomics to investigate the interaction of leukaemic stem cells and immune cells in the cancer microenvironment. Amy has also completed a post graduate certificate in Intellectual Property from Bournemouth University.

Since joining HGF, she has experience with client management, IP landscaping, drafting and prosecution, including UK and European prosecution. In most recent years, Amy has experience in the cell and gene therapy field, with particular experience in programmable gene therapy technologies and synthetic promoters.

Specialisms

Industries

Services

Qualifications

Patent Attorney

Chartered (UK)
Europe

MSCI

MSci in Immunology

PHD

PhD in Cancer Sciences

POSTGRADUATE DIPLOMA OR CERTIFICATE

Postgraduate Certificate Intellectual Property

Publications

NK Cell Therapy – an IP update

View publication online

New Practice at the EPO: Divisional Applications and Sequence Listings

View publication online

The EPO ‘How To’ guide for antibody applications in Europe

View publication online

CSR

Amy is a member of the IP Inclusive Scotland Committee.

Related News

Office Closed Dates December 2025 / January 2026

HGF Office Closed Dates December 2025 / January 2026   UK Thursday 25 and Friday 26 December 2025 CLOSED Thursday 1 January 2026* CLOSED * Friday 2 January 2026 – …

Read article

PRESS RELEASE – HGF strengthens European presence with three new Partners in France and Germany

HGF is pleased to announce the arrival of three new partners, further strengthening its European presence. Two partners will be joining the firm’s fast-growing French practice, and one will join …

Read article

The EPO Board of Appeal comments on the scope of the morality exclusion from patentability

The recent decision, T1553/22 of the Board of Appeal required the Board to consider the scope of the exclusions from patentability under Article 53(a) EPC. The invention in this case …

Read article

The Antibody Series #5 | Epitope-defined antibody claims: when “binds to this epitope” becomes a risk of insufficiency

The Boards of Appeal of the EPO (BoA) are the appeal body that reviews decisions made at the EPO; here, they reviewed an appeal in opposition proceedings after the revocation …

Read article

The Deity Shoes case: a question of design activity and the constraints on a designer’s freedom

The footwear brand Deity Shoes sought to enforce their Community Design rights, both registered and unregistered, against Mundorama Confort and Stay Design. However, Mundorama Confort and Stay Design found fault …

Read article

The Antibody Series #4 | pH points in antibody claims: when “same pH ” becomes an addition of matter

The Boards of Appeal of the EPO (BoA) are the appeal body that reviews EPO decisions; in this case, they reviewed a revocation in opposition of a patent relating to …

Read article

The Antibody Series #3 | Antibody code names in claims: why “ACZ885” is not sufficient to define the antibody

The Boards of Appeal of the EPO (BoA) are the appeal body that reviews EPO decisions. In this case, they examined a claim that identified an antibody by an internal …

Read article
See all updates

Let's talk

If you would like to discuss how HGF could help you, contact one of our IP specialists.

Contact us